Locked

Loading

Terms of Service

Click the Terms tab at the bottom of the app before using TreatHF (“the Product”) to read the full Terms of Service and License Agreement (the “Agreement”) which governs the use of the Product. The Agreement includes, among other detailed terms and conditions, certain disclaimers of warranties by the American College of Cardiology Foundation (“ACCF”) and requires the user to agree to release ACCF from any and all liability arising in connection with your use of the Product. By using the Product, you accept and agree to be bound by all of the terms and conditions set forth in the Agreement, including such disclaimers and releases. If you do not accept the terms and conditions of the Agreement, you may not proceed to use the Product. The Agreement is subject to change from time to time, and your continued use of the Product constitutes your acceptance of and agreement to be bound by any revised terms of the Agreement.

About TreatHF

  • TreatHF is for use by clinicians to specifically help optimize pharmacological therapy for chronic symptomatic heart failure patients with reduced ejection fraction (stage C HFrEF patients). However, drug therapy should be considered and implemented as just one component of the comprehensive management of a heart failure patient, along with suitable lifestyle management, specialty referrals, and any other treatment as needed.
  • Advice in this app is derived from either ACC/AHA/HFSA Heart Failure Guideline and Guideline updates, or ACC’s Expert Consensus Heart Failure decisions pathways, and is labeled as such.
  • The information in this app is based on a specific set of guideline-based patient indications. Use of this app assumes clinicians will conduct a full evaluation of the patient, consult relevant medical specialists as needed, utilize a team based approach to optimize therapy, and consider patient preferences in all medical decision making.

How to Use TreatHF

  • Evaluation Screen: Enter your patient’s indications.
  • Advice Screen: Review a quick summary of suggested next steps for your patient based on entered indications.
  • Email: Email yourself a summary of suggested next steps for help in forming a care plan.
  • Therapy Reference screen: Reference detailed information on the use of each therapy.

Do not show me this again

Indicate for stage C HFrEF Patient:

Reset

HF Assessment Parameters

Error message Select one of the options below Data message
Error message Select one of the options below Data message

Background Medications

RAS Inhibitor

Error Select one of the options above
Select one of the options above

If ARNI/ACEI/ARB not indicated for this patient:

Evidence-Based Beta Blocker

Error Select one of the options above
Error Select one of the options above

If beta blocker not indicated for this patient:

Additional Medications

Select one or many of the options above

Diuretic(s)

Select one of the options above

Further Indications

Indications for Additional/Alternate Therapies

Indications for Modified Dosing




Below are suggested next steps for this patient based on the entered indications. Indications collected in this app represent only those covered by ACC/AHA/HFSA guidelines, and should serve as a starting point. Final treatment decisions should be made after a full evaluation of the patient and discussion of patient preferences. In addition, the scope of this app focuses on pharmacological treatment for HFrEF. However, medical therapy should be considered and implemented as just one component of the comprehensive management of a heart failure patient, along with suitable lifestyle management, specialty referrals, and any other treatment as needed.

To help optimize use of medical therapy, review expert consensus guiding principles.


Therapy Considerations

Device Therapy

Referral and Symptom Progression

General Resources

References

Maddox T, Januzzi, J, Allen L, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021;77:772–810.


Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/ AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:776–803


Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62: e147–239.


Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022 May, 79 (17) e263–e421.​


Amsterdam E, Wenger N, Brindis R, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2014 Dec, 64 (24) e139–e228.​


Elissa Driggin, Thomas M. Maddox, Keith C. Ferdinand, et al. ACC Health Policy Statement on Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. Volume 77, Issue 15, 2021, Pages 1938-1948, ISSN 0735-1097.​

About the App

When was TreatHF last updated?

March 2024

The app was updated in March 2021 to include content from the 2021 Update to the 2017 Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment. New content includes information regarding angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors.

How can I provide feedback?

Click here to fill out our feedback survey

What is the target patient population?

This app is meant for use by clinicians in regards to chronic, symptomatic, heart failure patients with reduced ejection fraction (stage C HFrEF).

How is TreatHF meant to be used?

TreatHF helps clinicians determine which therapies are suggested for their patients with stage C HFrEF and provides guidance on the use of each therapy.

To use the app:

  1. Enter patient information on the Evaluation screen.
    • Indicate patient’s current use of background medications, and their response to those medications.
    • Enter any further indications the patient might have for additional medication or device therapy.
  2. View individualized next steps on the Advice screen.
    • Review advice for titrating current medications.
    • See what additional medications are suggested for your patient based on their indications.
    • Email yourself a summary of the next steps as a basis for a medication plan.
  3. Reference detailed information regarding each therapy on the Therapy Reference screen.
    • Access information regarding initiation, titration, monitoring, contraindications and cautions for each medication recommended for the treatment of patients with stage C HFrEF.
    • View expert consensus guidance on optimizing a medication plan for your patient and improving adherence.

Information in this app is derived from the 2021 Update to the 2017 Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment, the 2017 ACC/ AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure, and the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Indications collected in the app reflect the evidence-based indications outlined in these documents, and are meant to serve as a starting point. They do not represent the full list of considerations for prescribing and optimizing a medication or other clinical therapy, nor do they take into account contraindications. Use of this app assumes clinicians will conduct a full evaluation of the patient, consult relevant medical specialists as needed, utilize a team based approach to optimize therapy, and consider patient preferences in all medical decision making.

The information and recommendations in this app are meant to support clinical decision making. They are not meant to represent the only or best course of care, or replace clinical judgment. Therapeutic options should be determined after discussion between the patient and their care provider.

How was TreatHF Developed?

App content and design was refined and vetted by ACC member clinicians, and through user testing with clinicians practicing in relevant specialties.

TreatHF was developed as part of an ongoing effort at the ACC to facilitate access and implementation of ACC clinical policy at the point of care, and as part of ACC’s Succeed in Managing Heart Failure (SIMHF) Initiative, a multi-disciplinary quality program designed to improve care for heart failure patients. SIMHF is supported by Novartis.

Where can I go if I have questions?

For Support 

Call: (202) 375-6000, ext. 5603 or (800) 253-4636 

Email: membercare@acc.org

Terms of Service

TreatHF Terms of Service and License Agreement

This Terms of Service and License Agreement constitutes a legal agreement (collectively, the "Agreement") between the American College of Cardiology Foundation ("ACCF") and You and your agents ("You") for the use of the TreatHF (the "Product"), whether You use the mobile application version of the Product or the web version of the Product. The Product allows You to access certain content included in the Product ("Content") relating to suggested use of therapies to help treat chronic symptomatic heart failure with reduced ejection fraction.

By using the Product, You accept and agree to be bound by all of the terms and conditions set forth in this Agreement. If You do not wish to accept the terms and conditions of this Agreement, You may not proceed to use the Product.

ACCF may change the terms of this Agreement from time to time without further notice directly to You. When the terms are changed, ACCF will post a general conspicuous notice. If You do not agree with the revised terms, please discontinue use of the Product immediately. Your continued use of the Product following such notice constitutes your acceptance of and agreement to be bound by any revised terms of the Agreement. This Agreement expressly incorporates by reference and includes rules or disclaimers that may be posted and updated within the Product or communicated to You from time to time.


Term and Termination

ACCF may terminate your access and/or the Product at any time. You agree that any termination of your access to the Product shall not result in any liability or other obligation of ACCF to You, or any third party in connection with such termination.


Intellectual Property Rights

This Product, including the information, text, graphics, images, audio and video files, trademarks and other materials that may be contained therein (collectively "Content"), is owned by ACCF and/or its suppliers and is protected by patents, copyrights, trademarks, and other proprietary rights. Except as specifically provided in this Agreement, your use of the Product shall be governed and constrained by applicable patent, copyright, trademark and other intellectual property laws.
ACCF grants You a limited, nonexclusive, nontransferable, revocable license to utilize and access the Product for your noncommercial, personal use according to the terms and conditions in this Agreement. You may not modify, publish, transmit, participate in the transfer or sale of, reproduce, create derivative works from, distribute, perform, display, incorporate into another website, or in any other way exploit the Service and/or any of the Content, in whole or in part. Except as expressly granted by this Agreement, You acquire no right, title or interest in the Product or the Content or other data or materials incorporated in the Product. ACCF, ACC or affiliates or licensors thereof shall retain all right, title and interest in the Product and Content.


Limitation of Liability

TO THE FULLEST EXTENT ALLOWED BY APPLICABLE LAW, ACCF HEREBY DISCLAIMS, AND IN NO EVENT SHALL ACCF OR ANY PARTY INVOLVED IN CREATING OR PRODUCING THE PRODUCT BE LIABLE FOR, ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES, INCLUDING WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS, GOODWILL, USE, DATA LOSS, OR OTHER LOSSES, WHETHER IN AN ACTION OF CONTRACT, NEGLIGENCE OR OTHER TORTIOUS ACTION, EVEN IF ACCF HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, RESULTING FROM: (i) THE USE OR INABILITY TO USE THE PRODUCT, (ii) THE COST OF ANY SUBSTITUTE PRODUCTS AND/OR SERVICES RESULTING FROM ANY PRODUCTS, DATA, INFORMATION OR SERVICES OBTAINED OR WHICH YOU WERE UNABLE TO OBTAIN OR TRANSACTIONS EFFECTED OR FAILED TO BE EFFECTED, (iii) THE USE OR INABILITY TO USE ANY THIRD PARTY APPLICATIONS CONTAINED WITHIN THE PRODUCT, OR (iv) ANY MATTER OTHERWISE RELATED TO YOUR USE OF THE PRODUCT.


Release of Liability

You assume all risks associated with use of the Product including, but not limited to any harm, injury or damages resulting directly or indirectly from the use of the Product, all such risks being known and understood by You. In consideration of your use of the Product, You, for yourself and anyone entitled to act on your behalf, waive and forever release ACCF, its officers, trustees, employees, representatives and successors from all claims and liabilities of any kind arising out of your use or misuse of the Product.


Indemnification

You hereby agree to indemnify, save and hold ACCF, its directors, officers, shareholders, parents, subsidiaries, affiliates, agents and licensors harmless from and against any and all claims, liability, losses, damages and costs, including, without limitation, reasonable attorneys' fees and costs, arising out of your use or misuse of the Product or Content, or any violation of this Agreement. ACCF assumes the right, at your expense, to assume the exclusive defense and control of any matter for which you are required to indemnify ACCF, and you agree to cooperate with ACCF’s defense of these claims. ACCF will use reasonable efforts to notify you of any such claim, action, or proceeding upon becoming aware of it.


Disclaimer of Warranties

THE PRODUCT AND CONTENT ARE PROVIDED ON AN "AS IS" AND "AS AVAILABLE" BASIS. ACCF AND ITS SUPPLIERS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND WITH RESPECT TO THE PRODUCT OR CONTENT, WHETHER EXPRESS OR IMPLIED, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT. ACCF MAKES NO WARRANTY THAT THE PRODUCT AND/OR ANY CONTENT THEREIN WILL MEET YOUR REQUIREMENTS, OR WILL BE UNINTERRUPTED, TIMELY, SECURE, CURRENT, ACCURATE, COMPLETE OR ERROR-FREE OR THE RESULTS THAT MAY BE OBTAINED BY USE OF THE PRODUCT OR ANY CONTENT THEREIN WILL BE ACCURATE OR RELIABLE. YOU UNDERSTAND AND ACKNOWLEDGE THAT YOUR SOLE AND EXCLUSIVE REMEDY WITH RESPECT TO ANY DEFECT IN OR DISSATISFACTION WITH THE PRODUCT IS TO CEASE ITS USE.

The Content on the Product is presented as an educational service intended for licensed healthcare professionals. While the Content in the Product is about specific medical and healthcare issues, the Content is not a substitute for or replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions.

The views and opinions expressed are those of the contributing authors and editors and do not necessarily represent the views of the ACCF. The material is not intended to present the only, or necessarily best, methods or procedures for the medical situations addressed, but rather is intended to represent an approach, view, statement or opinion.

Any reference to a specific therapy or commercial product in this Product does not constitute a guarantee or endorsement by ACCF of the quality or value of such therapy or product or any claims made by the manufacturer of such therapy or commercial product.

In addition, any statements about such therapy or commercial products are solely based on published clinical prediction rules and estimates of drug treatment effects from published clinical studies and do not represent an ACCF endorsement or evaluation of these products.


Force Majeure

ACCF will be excused from performance under this Agreement and will not be liable or considered in default under this Agreement in the event that the Product is unavailable for any period of time, or if ACCF is otherwise unable to perform its obligations hereunder, in whole or in part, as a result of a Force Majeure Event. For purposes of this Section, "Force Majeure Event" means an event or series of events caused by or resulting from any of the following: (1) weather conditions or other elements of nature or acts of God; (2) government regulation; (3) quarantines or embargoes; (4) telecommunications, network, computer, server or Internet downtime; (5) unauthorized access to ACCF's information technology systems by third parties; or (6) any other causes beyond the reasonable control of ACCF.


No Assignment

This Agreement is personal to You, and You may not assign your rights or obligations to anyone.


No Waiver

Neither failure nor delay on the part of any party to exercise any right, remedy, power or privilege hereunder nor course of dealing between the parties shall operate as a waiver thereof, or of the exercise of any other right, remedy, power or privilege. No term of this Agreement shall be deemed waived, and no breach consented to, unless such waiver or consent shall be in writing and signed by the party claimed to have waived or consented. No waiver of any rights or consent to any breaches shall constitute a waiver of any other rights or consent to any other breach.


Severability

If any provision in this Agreement is held invalid or unenforceable under applicable law, the remaining provisions shall continue in full force and effect.


Governing Law

This Agreement will be governed by and construed exclusively in accordance with the laws of the District of Columbia, USA, without regard to its conflicts of law principles and, to the extent applicable, the federal laws of the United States. If a dispute arises between ACCF and You, You hereby agree to submit such dispute to non-binding mediation, followed by binding arbitration, if necessary. Both the mediation and arbitration will be conducted by JAMS applying the laws of the District of Columbia without regard to its conflicts of laws principles and in the District of Columbia as venue.


Certification

I hereby certify that I understand and agree to the terms stated in this Agreement and that this Agreement applies to my initial use of the Product and all other subsequent uses of the Product.

BY USING THIS PRODUCT, I HEREBY AFFIRM THAT I HAVE READ, FULLY UNDERSTAND, AND AGREE TO THE ABOVE STATEMENTS.

News

Welcome to ManageMR

Welcome to the News feature of the ManageMR app. Check this tab for relevant research and articles from the medical community, as well as updates on related guidelines, tools, and events from the American College of Cardiology.

Below are suggested next steps for this patient based on the entered indications. Indications collected in this app represent only those covered by ACC/AHA/HFSA guidelines, and should serve as a starting point. Final treatment decisions should be made after a full evaluation of the patient and discussion of patient preferences. In addition, the scope of this app focuses on pharmacological treatment for HFrEF. However, medical therapy should be considered and implemented as just one component of the comprehensive management of a heart failure patient, along with suitable lifestyle management, specialty referrals, and any other treatment as needed.

To help optimize use of medical therapy, review expert consensus guiding principles.


Therapy Considerations

Device Therapy

Referral and Symptom Progression